From research to industry
The French Alternative Energies and Atomic Energy Commission (CEA) is a key player in research, development and innovation.
Discover the main research areas on which the CEA works.
Find the latest scientific and institutional news of the CEA.
The CEA publishes various scientific and technical periodicals and videos. Through them, you can discover the CEA’s major research topics and the latest technological innovations produced by its laboratories.
Press release | Partnerships | Health ＆ life sciences | Innovation for industry
GTP Nano, a contract development and manufacturing organization (CDMO) serving the pharmaceutical industry, announced the production of its first clinical batches at its Toulouse, France plant. A new entrant on the nanodrug market, GTP Nano is leveraging an original partnership with research organization CEA that includes ongoing support with nanoformulation and the development of the associated manufacturing processes, as well as with nanocharacterization.
The CEA has been conducting R&D in biomaterials, bioprocesses and bioengineering for more than a decade. The institute invented a lipid nanoparticle (LNP) nanovectorization technology called Lipidots®, protected by more than fifteen patents. Lipidots® technology offers stealth, targeted, biocompatible drug delivery. The CEA develops milliliter-scale nanodrug manufacturing processes, and then scales them up to a liter before they are transferred to GTP Nano for scale-up to several liters (for GMP-compliant processes) for the manufacturing of clinical and commercial batches.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.